Embryonic and adult stem cell therapy

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Brignier, Anne C ^a   Gewirtz, Alan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cell therapy; gene therapy; human embryonic stem cells; induced pluripotent stem cells; regenerative medicine; Stem cells

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMYOTROPHIC LATERAL SCLEROSIS; APLASTIC ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER THERAPY; CANCER TRANSPLANTATION; CELL ISOLATION; CELL NUCLEUS; CELL REGENERATION; CELL TYPE; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CROHN DISEASE; EMBRYO; EMBRYONIC STEM CELL; ENRICHMENT CULTURE; FANCONI ANEMIA; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEART MUSCLE CELL; HUMAN; IMMUNE DEFICIENCY; INBORN ERROR OF METABOLISM; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CARCINOMA; LYMPHATIC LEUKEMIA; LYMPHOMA; MEDICAL ETHICS; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; MYELOMA; MYELOPROLIFERATIVE DISORDER; NERVE INJURY; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THALASSEMIA; TISSUE ENGINEERING;

ADULT STEM CELLS; ANIMALS; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; HUMANS; REGENERATIVE MEDICINE; STEM CELL NICHE; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE THERAPY; TRANSCRIPTIONAL ACTIVATION;

EID: 76749102879     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.032     Document Type: Article

References (80)

1. Till J.E., and McCulloch E.A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14 (1961) 213-222
2. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998) 1145-1147
3. Takahashi K., and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006) 663-676
4. Battey JF Jr, Cole LK, Goldthwaite CA Jr. Regenerative Medicine. Department of Health and Human Services. August 2006. http://stemcells.nih.gov/info/scireport/2006report.htm. Accessed December 15, 2009.
5. Klimanskaya I., Chung Y., Becker S., Lu S.J., and Lanza R. Human embryonic stem cell lines derived from single blastomeres. Nature 444 (2006) 481-485
6. Turnpenny L., Brickwood S., Spalluto C.M., Piper K., Cameron I.T., Wilson D.I., et al. Derivation of human embryonic germ cells: an alternative source of pluripotent stem cells. Stem Cells 21 (2003) 598-609
7. Revazova E.S., Turovets N.A., Kochetkova O.D., Kindarova L.B., Kuzmichev L.N., Janus J.D., et al. Patient-specific stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells 9 (2007) 432-449
8. Conrad S., Renninger M., Hennenlotter J., Wiesner T., Just L., Bonin M., et al. Generation of pluripotent stem cells from adult human testis. Nature 456 (2008) 344-349
9. Gurdon J.B., and Melton D.A. Nuclear reprogramming in cells. Science 322 (2008) 1811-1815
10. French A.J., Adams C.A., Anderson L.S., Kitchen J.R., Hughes M.R., and Wood S.H. Development of human cloned blastocysts following somatic cell nuclear transfer with adult fibroblasts. Stem Cells 26 (2008) 485-493
11. Cowan C.A., Atienza J., Melton D.A., and Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 309 (2005) 1369-1373
12. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007) 861-872
13. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007) 1917-1920
14. Raya A., Rodriguez-Piza I., Guenechea G., Vassena R., Navarro S., Barrero M.J., et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460 (2009) 53-59
15. Chin M.H., Mason M.J., Xie W., Volinia S., Singer M., Peterson C., et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5 (2009) 111-123
16. Mitalipova M.M., Rao R.R., Hoyer D.M., Johnson J.A., Meisner L.F., Jones K.L., et al. Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol 23 (2005) 19-20
17. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118 (2008) 3132-3142
18. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., and Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 322 (2008) 949-953
19. Stadtfeld M., Nagaya M., Utikal J., Weir G., and Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 322 (2008) 945-949
20. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26 (2008) 1269-1275
21. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4 (2009) 381-384
22. Eminli S., Foudi A., Stadtfeld M., Maherali N., Ahfeldt T., Mostoslavsky G., et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 41 (2009) 968-976
23. Flomenberg N., Devine S.M., Dipersio J.F., Liesveld J.L., McCarty J.M., Rowley S.D., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106 (2005) 1867-1874
24. Martin-Rendon E., Sweeney D., Lu F., Girdlestone J., Navarrete C., and Watt S.M. 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang 95 (2008) 137-148
25. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (2006) 315-317
26. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3+ regulatory T cells. Stem Cells 26 (2008) 212-222
27. Demirer T., Barkholt L., Blaise D., Pedrazzoli P., Aglietta M., Carella A.M., et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 5 (2008) 256-267
28. Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML?. Best Pract Res Clin Haematol 20 (2007) 85-90
29. Cutler C., Giri S., Jeyapalan S., Paniagua D., Viswanathan A., and Antin J.H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 19 (2001) 3685-3691
30. Aversa F., Terenzi A., Tabilio A., Falzetti F., Carotti A., Ballanti S., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
31. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
32. Takahashi S., Ooi J., Tomonari A., Konuma T., Tsukada N., Oiwa-Monna M., et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 109 (2007) 1322-1330
33. Lu X., Kondo Y., Takamatsu H., Ohata K., Yamazaki H., Takami A., et al. CD16 + CD56- NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect. Eur J Haematol 81 (2008) 18-25
34. Komanduri K.V., St John L.S., de Lima M., McMannis J., Rosinski S., McNiece I., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 110 (2007) 4543-4551
35. Ruggeri A., de Latour R.P., Rocha V., Larghero J., Robin M., Rodrigues C.A., et al. Double cord blood transplantation in patients with high risk bone marrow failure syndromes. Br J Haematol 143 (2008) 404-408
36. Robinson S.N., Ng J., Niu T., Yang H., McMannis J.D., Karandish S., et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 37 (2006) 359-366
37. Muraro P.A., Douek D.C., Packer A., Chung K., Guenaga F.J., Cassiani-Ingoni R., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 201 (2005) 805-816
38. Bayer A.L., Jones M., Chirinos J., de Armas L., Schreiber T.H., Malek T.R., et al. Host CD4 + CD25 + T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood 113 (2009) 733-743
39. Burt R.K., Loh Y., Pearce W., Beohar N., Barr W.G., Craig R., et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 299 (2008) 925-936
40. Wan C.D., Cheng R., Wang H.B., and Liu T. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int 7 (2008) 29-33
41. Ball L.M., Bernardo M.E., Roelofs H., Lankester A., Cometa A., Egeler R.M., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110 (2007) 2764-2767
42. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008) 1579-1586
43. Shapiro A.M., Ricordi C., Hering B.J., Auchincloss H., Lindblad R., Robertson R.P., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355 (2006) 1318-1330
44. Xu X., D'Hoker J., Stange G., Bonne S., De Leu N., Xiao X., et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 132 (2008) 197-207
45. Kroon E., Martinson L.A., Kadoya K., Bang A.G., Kelly O.G., Eliazer S., et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 26 (2008) 443-452
46. Zhou Q., Brown J., Kanarek A., Rajagopal J., and Melton D.A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455 (2008) 627-632
47. Lee R.H., Seo M.J., Reger R.L., Spees J.L., Pulin A.A., Olson S.D., et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A 103 (2006) 17438-17443
48. Couri C.E., Oliveira M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301 (2009) 1573-1579
49. Arvidsson A., Collin T., Kirik D., Kokaia Z., and Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 8 (2002) 963-970
50. Mackay-Sim A., Feron F., Cochrane J., Bassingthwaighte L., Bayliss C., Davies W., et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain 131 (2008) 2376-2386
51. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
52. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
53. Braak H., and Del Tredici K. Assessing fetal nerve cell grafts in Parkinson's disease. Nat Med 14 (2008) 483-485
54. Keene C.D., Chang R.C., Leverenz J.B., Kopyov O., Perlman S., Hevner R.F., et al. A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol 117 (2009) 329-338
55. Lévesque M.F., Neuman T., and Rezak M. Therapeutic microinjection of autologous adult human neural stem cells and differentiated neurons for Parkinson's disease: five-year post-operative outcome. Open Stem Cell J 1 (2009) 20-29
56. Levy Y.S., Bahat-Stroomza M., Barzilay R., Burshtein A., Bulvik S., Barhum Y., et al. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy 10 (2008) 340-352
57. Murrell W., Wetzig A., Donnellan M., Feron F., Burne T., Meedeniya A., et al. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease. Stem Cells 26 (2008) 2183-2192
58. Cho M.S., Lee Y.E., Kim J.Y., Chung S., Cho Y.H., Kim D.S., et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A 105 (2008) 3392-3397
59. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 105 (2008) 5856-5861
60. Kondziolka D., Steinberg G.K., Wechsler L., Meltzer C.C., Elder E., Gebel J., et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg 103 (2005) 38-45
61. Savitz S.I., Dinsmore J., Wu J., Henderson G.V., Stieg P., and Caplan L.R. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis 20 (2005) 101-107
62. Nakatomi H., Kuriu T., Okabe S., Yamamoto S., Hatano O., Kawahara N., et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 110 (2002) 429-441
63. Yoon S.H., Shim Y.S., Park Y.H., Chung J.K., Nam J.H., Kim M.O., et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: phase I/II clinical trial. Stem Cells 25 (2007) 2066-2073
64. van Laake L.W., Passier R., Monshouwer-Kloots J., Verkleij A.J., Lips D.J., Freund C., et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res 1 (2007) 9-24
65. Puymirat E., Geha R., Tomescot A., Bellamy V., Larghero J., Trinquart L., et al. Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells?. Mol Ther 17 (2009) 176-182
66. Hamamoto H., Gorman III J.H., Ryan L.P., Hinmon R., Martens T.P., Schuster M.D., et al. Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Ann Thorac Surg 87 (2009) 794-801
67. van der Bogt K.E., Sheikh A.Y., Schrepfer S., Hoyt G., Cao F., Ransohoff K.J., et al. Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation 118 suppl (2008) S121-S129
68. Smith R.R., Barile L., Cho H.C., Leppo M.K., Hare J.M., Messina E., et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115 (2007) 896-908
69. Dill T., Schachinger V., Rolf A., Mollmann S., Thiele H., Tillmanns H., et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 157 (2009) 541-547
70. Chen S.L., Fang W.W., Ye F., Liu Y.H., Qian J., Shan S.J., et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94 (2004) 92-95
71. Abdel-Latif A., Bolli R., Tleyjeh I.M., Montori V.M., Perin E.C., Hornung C.A., et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167 (2007) 989-997
72. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360 (2009) 447-458
73. Ott M.G., Schmidt M., Schwarzwaelder K., Stein S., Siler U., Koehl U., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12 (2006) 401-409
74. Mavilio F., Pellegrini G., Ferrari S., Di Nunzio F., Di Iorio E., Recchia A., et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 12 (2006) 1397-1402
75. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118 (2008) 3143-3150
76. Wu X., Li Y., Crise B., and Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300 (2003) 1749-1751
77. Montini E., Cesana D., Schmidt M., Sanvito F., Ponzoni M., Bartholomae C., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24 (2006) 687-696
78. Wu L.C., Sun C.W., Ryan T.M., Pawlik K.M., Ren J., and Townes T.M. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108 (2006) 1183-1188
79. Kim S.M., Lim J.Y., Park S.I., Jeong C.H., Oh J.H., Jeong M., et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 68 (2008) 9614-9623
80. Leist M., Bremer S., Brundin P., Hescheler J., Kirkeby A., Krause K.H., et al. The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy. ALTEX 25 (2008) 163-190